Authors' Reply: Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?
作者信息
Barratt Jonathan, Garlo Katherine, Kateifides Andreas, Lafayette Richard
机构信息
Mayer IgA Nephropathy Laboratories, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Alexion, AstraZeneca Rare Disease, Boston, Massachusetts.
出版信息
J Am Soc Nephrol. 2025 May 1;36(5):986-987. doi: 10.1681/ASN.0000000674. Epub 2025 Mar 26.
Abstract
摘要
相似文献
1
Authors' Reply: Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?作者回复：IgA肾病中的补体抑制疗法：完全抑制还是选择性抑制？
J Am Soc Nephrol. 2025 May 1;36(5):986-987. doi: 10.1681/ASN.0000000674. Epub 2025 Mar 26.
2
Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report.用iptacopan成功靶向替代补体途径治疗IgA肾病：一例病例报告。
Swiss Med Wkly. 2025 Jun 30;155:4435. doi: 10.57187/s.4435.
3
Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy.IgA肾病患者补体调节蛋白的肾小球沉积及血清水平
Clin Nephrol. 1984 Jun;21(6):335-40.
4
Complement activation in IgA nephropathy.补体激活在 IgA 肾病中的作用。
Semin Immunopathol. 2021 Oct;43(5):679-690. doi: 10.1007/s00281-021-00882-9. Epub 2021 Aug 11.
5
The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.补体蛋白作为 IgA 肾病治疗靶点的新作用。
Front Immunol. 2019 Mar 19;10:504. doi: 10.3389/fimmu.2019.00504. eCollection 2019.
6
Collectin11 and Complement Activation in IgA Nephropathy.收集素 11 和 IgA 肾病中的补体激活。
Clin J Am Soc Nephrol. 2021 Dec;16(12):1840-1850. doi: 10.2215/CJN.04300321. Epub 2021 Oct 6.
7
Authors' Reply: Ravulizumab in IgA Nephropathy: A Promising Step Toward Disease Modification?作者回复：ravulizumab治疗IgA肾病：朝着疾病改善迈出的有希望的一步？
J Am Soc Nephrol. 2025 Aug 22. doi: 10.1681/ASN.0000000832.
8
Combined Effects of the Serum IgA/C3 Ratio and Glomerular C3 Staining on the Renal Outcome in Adult Immunoglobulin A Nephropathy.血清 IgA/C3 比值与肾小球 C3 染色对成人 IgA 肾病肾脏结局的联合影响。
Kidney Blood Press Res. 2024;49(1):246-257. doi: 10.1159/000536114. Epub 2024 Feb 21.
9
Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?IgA肾病中的补体抑制疗法：全面抑制还是选择性抑制？
J Am Soc Nephrol. 2025 May 1;36(5):984-985. doi: 10.1681/ASN.0000000673. Epub 2025 Mar 26.
10
The Proportion of New-Onset Microangiopathic Lesions in IgA Nephropathy is Increased After COVID-19 Pandemic in China.中国新冠疫情后IgA肾病中新发微血管病变的比例增加。
Kidney Med. 2025 Jun 3;7(8):101043. doi: 10.1016/j.xkme.2025.101043. eCollection 2025 Aug.
本文引用的文献
1
Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?IgA肾病中的补体抑制疗法：全面抑制还是选择性抑制？
J Am Soc Nephrol. 2025 May 1;36(5):984-985. doi: 10.1681/ASN.0000000673. Epub 2025 Mar 26.
2
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.ravulizumab治疗IgA肾病的疗效与安全性：一项2期随机双盲安慰剂对照试验
J Am Soc Nephrol. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25.
3
Association of C4d deposition with clinical outcomes in IgA nephropathy.IgA肾病中C4d沉积与临床结局的关联
Clin J Am Soc Nephrol. 2014 May;9(5):897-904. doi: 10.2215/CJN.09710913. Epub 2014 Feb 27.
4
Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.IgA 肾病中补体蛋白的排泄及其激活标志物 C5b-9 与肾功能的关系。
BMC Nephrol. 2011 Nov 23;12:64. doi: 10.1186/1471-2369-12-64.
5
The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells.膜攻击复合物C5b-9上调肾小管上皮细胞中的胶原蛋白基因表达。
Clin Exp Immunol. 2004 Apr;136(1):60-6. doi: 10.1111/j.1365-2249.2004.02411.x.
6
C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis.C5a在实验性免疫复合物肾小球肾炎的肾小管间质成分中起重要作用。
Clin Exp Immunol. 2002 Oct;130(1):43-8. doi: 10.1046/j.1365-2249.2002.01957.x.
Zotero 插件